AI Summary & Key Takeaways
AI InsightConclusion: There was no effect of serotonin level in the development of no-reflow, in patients to whom primary coronary percutaneous intervention was applied.
📌 3 Key Takeaways
Abstract
Objective: Our aim was to investigate the effects of serotonin, which is a severe vasoconstrictor agent, on the occurrence of no-reflow phenomenon. Methods: In this cross-sectional controlled study, 40 patients, admitted to our clinic with chest pain in the first 12 hours and underwent primary percutaneous coronary intervention because of acute myocardial infarction were enrolled. Patients with TIMI 0 grade basal flow and normal post-procedure flow were included in group 1 and patients with flow grade TIMI ≤were enrolled in group 2. To measure the serotonin levels, blood samples were collected from the coronary ostium before the procedure. Results: In group 1, there were 25 patients (20 males, 5 females) and the mean age was 58±11 years; in group 2 there were 15 patients (13 males, 2 females) and the mean age was 62±8 years. The mean serotonin level in platelet in group 1 was 476±208 ng/109 platelet and in group 2-542±273 ng/109 platelet. The difference was not statistically significant (p=0.39). When we compared the serum serotonin levels, it was 41.4±40.8 ng/ml for group 1, but 66.7±45.7 ng/ml for group 2. Although the serum serotonin levels were higher in group 2, the difference was not statistically significant (p=0.07). Conclusion: There was no effect of serotonin level in the development of no-reflow, in patients to whom primary coronary percutaneous intervention was applied.
Özet
Amaç: Çalışmamızın amacı, vazokonstriktör bir ajan olan serotoninin no-reflow fenomeni gelişimi üzerine olan etkisini araştırmaktı. Yöntemler: Bu enine-kesitli kontrollü çalışmaya akut miyokart enfarktüsü nedeniyle, göğüs ağrılarının ilk 12 saati içinde kliniğimize başvuran ve primer perkütan girişim uygulanan 40 hasta alındı. İşlem öncesi akım TIMI 0 iken işlem sonrası akım normal olanlar grup 1’i, işlem sonrası akım TIMI ≤2 olanlar grup 2’yi oluşturdu. Serotonin düzeyini ölçmek için işlem öncesi koroner ostiumdan kan alındı. Bulgular: Grup 1’de 25 hasta (20 erkek, 5 kadın) vardı, ortalama yaş 58±11 yıl idi; Grup 2’ de 15 hasta vardı (13 erkek, 2 kadın) ve ortalama yaş 62±8 yıl idi. Grup’1 de trombosit içi ortalama serotonin düzeyi 476±208 ng/109 trombosit ve grup 2’de 542±273 ng/109 trombosit idi. Fark istatistiksel olarak anlamlı değildi (p=0.39). Serum serotonin düzeyi grup’1 de 41.4±40.8 ng/ml, grup’2 de 66.7±45.7 ng/ml olarak bulundu. Aradaki fark anlamlı değildi (p=0.07). Sonuç: Primer perkütan girişim uygulananlarda serotonin düzeyinin no-reflow gelişimi üzerine etkisi yoktur.